Top news of the week: 07.07.2020.
Global Ocean Sampling Expedition, Venture capital financing, Shanghai, Sorbitol, Neurodegenerative diseases, Autoimmunity
Startups
RT @adamfeuerstein: Venter Institute, Yumanity, and other biopharma companies among recipients of PPP loans https://t.co/fipkqqwihk via @sheridan_kate
OpenVenter Institute, Yumanity, and other biopharma companies among recipients of PPP loans
The J. Craig Venter Institute got a loan worth more than $2 million, while neurodegeneration-focused startup Yumanity Therapeutics got more than $1 million.
Boehringer creates Shanghai hub to connect with Chinese R&D groups https://t.co/Wq9w0sUU6w https://t.co/fy6aVb9r3M
OpenBoehringer creates Shanghai hub to connect with Chinese R&D groups
Boehringer Ingelheim has opened a site in Shanghai to connect its R&D, business development and venture capital groups to Chinese drug developers. The site brings together all the units ...
Incensed Applied Therapeutics vows to end 'criminal activity' from short report https://t.co/pTTcNPRcjP https://t.co/ITFeQcHWi9
OpenIncensed Applied Therapeutics vows to end 'criminal activity' from short report
Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.
RT @bussgang: VC Q2 funding data shows early-stage investors growing more cautious: seed & angel deals dramatically down 58% YoY and $ down 38%.
The market may recover in Q3, but it was a heck of a lot harder to get new, early-stage capital last quarter.
https://t.co/qcCTOmbgTW
OpenQ2 2020 Global Venture Report: Funding Through The Pandemic
Despite the turmoil of an ongoing pandemic, global venture funding for the second quarter of 2020 was not as dire as we expected, but it was down from previous years.
British biotech Mission dubs Pfizer lead investor and new R&D partner https://t.co/2bp2gvKK8n https://t.co/kf05HYFWns
OpenBritish biotech Mission dubs Pfizer lead investor and new R&D partner
Pfizer is deepening its already long-term investment and partnership strategy with U.K.-based biotech Mission Therapeutics and its work on selectively inhibiting deubiquitylating enzymes.
RT @Big4BioPhilly: .@LifeSciencesPA's quarterly newsletter is here!
Check it out!
https://t.co/XSY1PdylxA
Open
The Repurpose.AI-LEO Pharma deal highlights a growing trend of drug makers turning to AI developers to streamline drug discovery
https://t.co/5PtA6UNq0N
OpenRepurpose.AI partnered with LEO Pharma to accelerate drug discovery
Repurpose.AI landed a deal with drug maker LEO Pharma to identify possible candidates for dermatology and inflammatory conditions.
On Heels of $100M Financing, #AnnexonBioSciences Aims to Tack On More Via IPO
- by @sarahdc
https://t.co/8eRFoXPGxH
$ALEC
OpenOn Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO
The same week Annexon Biosciences announced it had raised $100 million in private financing to advance its research of antibody drugs to treat